Stocks Health care PYXS

NASDAQ · Health care

Pyxis Oncology, Inc. (PYXS)

It posted a net loss of $88.7M. In fiscal 2025 capital spending exceeded operating cash flow by $63.5M. At June 30, 2026 it held $18.9M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.

What Pyxis Oncology, Inc. does

Pyxis Oncology, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker PYXS.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Where PYXS ranks in Health care

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What Pyxis Oncology, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. September 9, 2026
   Investor disclosure 8-K
2. September 8, 2026
   Executive or director change 8-K
3. August 28, 2026
   Securities offering prospectus 424B2
4. August 20, 2026
   Shelf registration to sell securities S-3
5. August 13, 2026
   Quarterly report 10-Q · period to June 30, 2026
6. August 13, 2026
   Quarterly results 8-K
7. July 10, 2026
   Passive stake (5% or more) SCHEDULE 13G
8. July 2, 2026
   Material agreement 8-K
9. July 2, 2026
   Passive stake changed SCHEDULE 13G/A
10. June 15, 2026
    Shareholder vote results 8-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 8, 2026. Insider transactions on SEC

Insider trades

What the people running Pyxis Oncology, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

All insider filings on SEC.gov · Where insiders are buying across the market

All filings on SEC EDGAR

Questions about PYXS

What does Pyxis Oncology, Inc. do?

Pyxis Oncology, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker PYXS.

Is Pyxis Oncology, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $88.7M.

When did Pyxis Oncology, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the investor disclosure from September 9, 2026.

Similar companies

Compare PYXS with

Compare PYXS with any company

Follow PYXS

Get an email when Pyxis Oncology, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow PYXS: get an email when it files

Where the numbers come from

Financial figures are the values Pyxis Oncology, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.